HEALTHCARE News & Analysis

We think a delay rather than an outright rejection for this company’s product is the likelier outcome, but the shares still look expensive.

Niche play with more growth potential than many investors give it credit for.

We assume that pharmaceutical tariffs will be enacted. While this could bring short-term margin pressure, we have not changed our valuations.

The ASX's biggest healthcare name saw its shares fall after reporting first-half results.

Find out how you can benefit from global megatrends. 

Shares in Australia's second biggest pathology operator have floundered in recent years. Shane Ponraj thinks better days could be ahead.

The steep market reaction comes after a recent announcement by the ACCC.

CSL's Behring division shone but markets were left underwhelmed by the company's guidance for 2025.

Shares are up 25% year to date but still screen as undervalued.

The shares are trading at a 27% discount to our fair value.